Hyperuricemia
Drug research and approvals for hyperuricemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 26 studies of hyperuricemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 4 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 26
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 3
- Evaluation of the Effect of Hyperuricemia on Alveolar Bone LossNCT07666126 · Not reported · Recep Tayyip Erdogan University Training and Research Hospital · starts Jun 10, 2026
- Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic HyperuricemiaNCT07613138 · Not applicable · Beijing Zhecheng Biotechnology Co., Ltd. · starts Jun 4, 2026
- A Study of IN026 in Participants With Refractory GoutNCT07587684 · Phase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · starts Jun 12, 2026
- Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support…NCT07400549 · Not applicable · China National Center for Cardiovascular Diseases · starts Jun 1, 2025
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and…NCT07362355 · Phase 2 · Jiangsu HengRui Medicine Co., Ltd. · starts Feb 9, 2026
- Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and HyperuricaemiaNCT07323095 · Phase 2 · Atom Therapeutics Co., Ltd · starts Oct 2, 2026
- A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing…NCT07280156 · Phase 2 · Protalix · starts Dec 22, 2025
- This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In…NCT07144332 · Not reported · Sohag University · starts Jul 13, 2025
- The Effects of a Probiotic Food Supplement in HyperuricaemiaNCT07141888 · Not applicable · Örebro University, Sweden · starts Dec 16, 2025
Approved 3
- RasburicaseUric acid oxidative enzyme
- FebuxostatXanthine dehydrogenase inhibitor
- LesinuradSolute carrier family 22 member 12 inhibitor
Phase 3 1
- AllopurinolXanthine dehydrogenase inhibitor
Phase 2 7
- SHR-4640Solute carrier family 22 member 12 inhibitor
- DotinuradSolute carrier family 22 member 12 inhibitor
- BenzbromaroneSolute carrier family 22 member 12 inhibitor
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- TopiroxostatXanthine dehydrogenase inhibitor
- VerinuradSolute carrier family 22 member 12 inhibitor
- UlodesinePurine nucleoside phosphorylase inhibitor
Phase 1 or earlier 2
- DiphenhydramineHistamine H1 receptor antagonist
- DexamethasoneGlucocorticoid receptor agonist
How its trials ended
186 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 34 whose ending is known, 62% met their primary endpoint, 12% missed it and 26% stopped early.
- Completed, result not reported8646%
- Status unknown3921%
- Ongoing2715%
- Met its primary endpoint2111%
- Stopped: enrollment or feasibility53%
- Missed its primary endpoint42%
- Stopped: other or unclear21%
- Stopped: sponsor or business decision11%
- Stopped: funding11%
| Jul 7, 2022 | KrystexxaTreatment of chronic gout in adult patients refractory to conventional therapy | Horizon Therapeutics Ireland DAC | Approved |
| Sep 14, 2010 | KrystexxaTreatment of chronic gout in adult patients refractory to conventional treatment | Horizon Therapeutics Ireland DAC | Approved |
| Jul 12, 2002 | ElitekInitial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving… | Sanofi-Synthelabo Research | Approved |
| Jun 6, 2005 | Polyethylene glycol-modified uricaseTreatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated | Swedish Orphan Biovitrum AB | Designated |
| Oct 11, 2000 | Recombinant urate oxidaseProphylaxis of chemotherapy-induced hyperuricemia. | Sanofi-Synthelabo Research | Designated |
| Sep 14, 1999 | Polyethylene glycol-modified uricaseProphylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy. | Swedish Orphan Biovitrum AB | Designated |
| Nov 9, 1998 | OxypurinolTreatment of hyperuricemia in patients intolerant to allopurinol. | Cardiome Pharma Corp. | Designated |
| Mar 28, 2019 | Febuxostat KrkaFebuxostat · generic | KRKA tovarna zdravil d.d. Novo mesto | EMA ↗ |
| Jun 15, 2017 | Febuxostat Viatris (previously Febuxostat Mylan)Febuxostat · generic | Viatris Limited | EMA ↗ |
| Feb 23, 2001 | FasturtecRasburicase | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA